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Abstract Acute renal failure (ARF) is uncommon in
childhood and there is little consensus on the appropriate
treatment modality when renal replacement therapy is
required. Members of the European Pediatric Peritoneal
Dialysis Working Group have produced the following
guidelines in collaboration with nursing staff. Good
practice requires early discussion of patients with ARF
with pediatric nephrology staff and transfer for investi-
gation and management in those with rapidly deteriorat-
ing renal function. Patients with ARF as part of multi-
organ failure will be cared for in pediatric intensive care
units where there should be access to pediatric nephrology
support and advice. The choice of dialysis therapy will
therefore depend upon the clinical circumstances, location
of the patient, and expertise available. Peritoneal dialysis
has generally been the preferred therapy for isolated
failure of the kidney and is universally available.
Intermittent hemodialysis is frequently used in renal units
where nursing expertise is available and hemofiltration is
increasingly employed in the intensive care situation.
Practical guidelines for and the complications of each
therapy are discussed.
Keywords Acute renal failure · Peritoneal dialysis ·
Hemofiltration · Hemodialysis · Guidelines
Introduction
Acute renal failure (ARF) is uncommon in childhood, but
its incidence may be increasing and modalities of
treatment changing with an increasing number of children
being treated in the intensive care unit (ICU) with multi-
organ failure. Traditionally children with ARF with renal
involvement were only treated with peritoneal dialysis,
but extracorporeal techniques are being increasingly used
in ICUs.
Members of the European Pediatric Dialysis Working
Group reviewed all modalities of renal replacement
therapy for ARF in children and developed the following
guidelines in collaboration with nursing staff during three
meetings and extensive e-mail discussion. There are no
randomized trials of renal replacement treatment in
children with ARF. The guidelines are based upon
published reports and consensus opinion to emphasize
good practice.
ARF is recognized when renal excretory function
declines rapidly. Rising values of plasma urea and
creatinine are usually accompanied by oliguria (<1 ml/
kg per hour), but occasionally patients may be polyuric.
The cause of ARF may be pre-renal, intrinsic, or post-
renal (obstructive) problems, and causes differ between
neonates and older children [1, 2, 3].
The incidence of ARF in children is hard to define, as
often renal insufficiency in the newborn and on ICUs is
conservatively managed by ICU staff. Outside the neo-
natal period, ARF is an uncommon condition accounting
for 8 referrals per million population per year to one
regional pediatric nephrology unit in the United Kingdom
[4].
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Fax: +44-115-9627759ARF may occur as isolated failure of the kidneys
alone, with other organ systems functioning normally, or
in association with multiple organ failure. The mortality
of the latter group is considerably higher, especially with
the growth in pediatric intensive care. For example, the
mortality in neonates and infants is 51% after cardiac
surgery for congenital heart defects [4], but only 3%–6%
for children with intrinsic renal disease such as hemolytic
uremic syndrome (HUS) in developed countries [5, 6].
The case mix in different units treating ARF, and
hence mortality and morbidity rates, will therefore vary
according to local clinical activity and resources [7, 8].
Many pediatric renal units will be close to pediatric ICUs
(PICUs) in hospitals that may offer cardiac surgery, liver
transplantation, and specialist treatment for metabolic
disorders, oncology patients, etc. [6]. Other renal units
may be in hospitals that do not have a PICU on site and
conversely there may be hospitals offering pediatric
intensive care with no specialist pediatric nephrology
service.
Recommendations
All children with ARF require discussion with a pediatric
nephrologist. Early transfer for investigation and man-
agement is essential in those with rapidly deteriorating
renal function or in those with hemodynamic or bio-
chemical disturbances (good practice) [9].
All children with ARF as part of multi-organ failure
require transfer to a designated regional pediatric ICU
where there should be access to pediatric nephrology
advice and support (good practice).
Rationale
Since there are few comprehensive regional pediatric
nephrology centers the distances that families may have
to travel can be considerable. Children with acute renal
impairment may be managed in local hospitals, but it is
essential that early referral is made, especially if children
have evidence of rapidly deteriorating renal function and
require an urgent histological diagnosis to determine if
immunosuppressive therapy or other treatment is re-
quired. Indications for referral include oligoanuria, espe-
cially if associated with fluid overload, hypertension,
hyperkalemia, hyponatremia, acidosis, or the need for
blood transfusion. Dialysis is often accompanied by early
nutritional support and pediatric nephrology units should
be equipped to provide the necessary medical and nursing
expertise, combined with dietetic and psychosocial sup-
port. The latter support is also important if the child is
managed conservatively.
Neonates and premature infants with ARF require
transfer to a tertiary neonatal unit with pediatric nephrol-
ogy team expertise. Patients with ARF and multi-organ
failure require prompt transfer to a designated regional
PICU.
The choice of dialysis therapy for ARF depends upon
the clinical circumstances, patient location, and expertise
available. Peritoneal dialysis (PD) has generally been
considered the preferred therapy if there is isolated failure
of the kidneys, such as HUS. It is regarded as a simpler
technique that is universally available. However, hemo-
filtration (HF) and hemodiafiltration (HDF) are increasing
in popularity in PICUs where the facilities to perform
hemodialysis (HD) may not be available. HD may be the
preferred mode of treatment in more-stable patients with
adequate vascular access treated on renal units where
specialist nurses are available.
Although extracorporeal techniques such as continuous
venovenous hemofiltration (CVVH) or continuous ven-
ovenous hemodiafiltration (CVVHDF) are used quite
frequently in adult ICUs, there is still limited expertise in
many PICUs. Such techniques are very dependent on
technology and are more costly than PD [10]. They are
also dependent upon the availability of appropriate
nursing expertise [11]. Such expertise can be developed
and maintained in units remote from the pediatric
nephrology center by an outreach service using a renal
critical care nurse educator [12].
Recommendation
There is no evidence for the optimum level of renal
function for starting renal replacement therapy nor for the
optimum dialysis modality. Advantages and disadvan-
tages are listed in Table 1. Consideration should be given
to establishing national and international databases to
collect these data along with patient outcomes [6, 13].
Table 1 Advantages and disadvantages of various modalities of renal replacement therapy for acute renal failure (CVVH continuous
venovenous hemofiltration, CVVHDF continuous venovenous hemodiafiltration)
Type Complexity Use in hypotension Efficiency Volume control Anticoagulation
Peritoneal dialysis Low Yes Moderate Moderate No
Intermittent hemodialysis Moderate No High Moderate Yes
CVVH Moderate Yes Moderate Good Yes
CVVHDF High Yes High Good Yes
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Acute PD
The main advantage of PD is that it is continuous therapy
that requires neither anticoagulation nor vascular access,
and the technique can be used in hemodynamically
unstable patients [14]. Acute PD can be performed in
units with no HD expertise and is effective in children of
all ages, including neonates [15, 16, 17, 18]. PD has been
used in treating acute pancreatitis, tumor lysis syndrome,
intoxications, metabolic diseases, and other pathological
conditions in children [19, 20, 21, 22]. The choice of PD
as therapy has always to be individualized, balancing
advantages against disadvantages.
Limitations in the use of PD
Inborn areas of metabolism in the newborn period lead to
acute accumulation of neurotoxic metabolites that can be
better removed using techniques such as CVVHDF [23,
24]. The latter technique requires good vascular access,
which can still be a major problem in small children [25].
Newborns with respiratory diseases, even if on ventilatory
treatment, can be treated with PD provided that the fill
and exchange volumes are adapted to the clinical
situation. However, caution is necessary in neonates with
necrotizing enterocolitis and older children with suspect-
ed bowel perforation [26].
Preparation for PD
Dialysis is only possible if the access provides free flow
in and out of the abdomen. The choice is between
catheters inserted at the bedside under sedation or the
placement of a chronic PD catheter by a pediatric surgeon
in the operating theater, or exceptionally at the bedside in
the ICU.
The rigid Trocath catheter with a stylet has largely
disappeared and surgically placed Tenckhoff catheters are
reported to have fewer complications [27, 28, 29].
However, small catheters for percutaneous placement
using a Seldinger technique are invaluable in providing
acute PD rapidly, especially in the neonatal PICU [13,
30].
Blockage by the omentum is always a risk with PD
catheters. If the catheter is to be placed surgically then
consideration should be given to partial omentectomy
[31].
In patients who are having a PD catheter inserted under
general anesthetic a cephalosporin antibiotic (20 mg/kg)
should be given as a single intravenous dose up to 1 h
prior to implantation of the catheter [32]. Any subsequent
accidental contamination should result in the use of
prophylactic antibiotics, e.g., cefuroxime 125 mg/l in the
dialysate for 48 h.
For catheters that are inserted percutaneously, prophy-
lactic antibiotics, e.g., cefuroxime 125 mg/l, should be
added to the dialysis fluid unless the patient is on
systemic treatment.
Heparin, 500 units/l, should be prescribed to prevent
catheter blockage with fibrin. This is generally main-
tained for the first 48 h, and longer if the PD fluid remains
slightly bloodstained [33, 34].
PD prescription
This needs to be individualized according to patient size
and condition. Automated PD machines are the preferred
method for delivering the individualized dialysis pre-
scription and accurately measuring ultrafiltration [30].
Such machines are now available that can deliver dialysis
volumes accurately down to 60 ml with 10-ml increments.
Although such machines now have improved accuracy of
ultrafiltration measurements, the dead space of the tubing
can reduce dialysis efficiency. A manual PD set can be
used, using burettes that can accurately measure inflow
and outflow, with the PD fluid warmed appropriately
[35]. With manual sets, attempts should be made to
maintain a closed drainage system, which can help reduce
the frequency of peritoneal contamination [36]. Such
manual PD sets are commercially available for neonatal
patients.
Choice of dialysis solution
The choice of dialysis solution will depend upon the
weight, blood pressure, and hydration status of the child,
bearing in mind the need to create nutritional space as part
of the management strategy [37].
The general principle is to commence with the lowest
concentration of glucose solution possible (1.36%), with
stepwise increments. Care is needed if 3.86% glucose
solution is required as (1) rapid ultrafiltration can occur
(especially in infants) and (2) hyperglycemia may develop
(especially in septic and multi-organ failure patients)
leading to hyperosmolarity and loss of effective ultrafil-
tration.
Icodextrine solutions need a longer dwell time to
obtain significant ultrafiltration and so are rarely indicat-
ed in ARF. Lactate-containing dialysis solutions are likely
to be replaced by bicarbonate solutions, which are being
evaluated in chronic PD. The routine use of bicarbonate
solutions should be considered in neonates or in patients
with reduced lactate metabolism or with lactic acidosis
[38, 39].
Practical points
Patients should be connected and automated PD or
manual cycles started immediately after catheter implan-
tation. Heparin (500 units/l) should be added to the
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peritoneal solute permeability [33, 34], but it can be
absorbed and care is needed in patients with coagulation
disorders.
Dialysis fill volumes of 10–20 ml/kg (300–600 ml/m2)
should be used initially, depending on the body size and
cycle in and out, until the dialysate becomes clear.
A PD program with 1-h dwells should be used during
the first 24 h. Shorter cycles can be considered initially if
hyperkalemia needs urgent treatment.
The program should be adjusted with increasing dwell
times and cycle fill volume (if no leakage problems) until
the desired fill volume (800–1,200 ml/m2) is achieved,
with adequate ultrafiltration and biochemical control [40].
High intraperitoneal pressure (IPP) can be a problem in
the first 2–3 days after surgical catheter insertion. The
measurement of IPP may limit the risk of leakage when
the fill volumes are being increased and allow optimized
pain management, but is not yet in routine use [41].
Inflow/outflow pain on PD usually diminishes with
time. Tidal dialysis is an alternative [42] and bicarbonate
dialysis should be considered [43].
The amount of ultrafiltration that is prescribed will
partly depend upon the volume of oral, nasogastric, or
total parenteral nutrition that is required, combined with
fluid for drugs. Ultrafiltration may not be enough without
the use of 2.27% or 3.86% glucose solutions.
The clinical, biochemical, and nutritional status of the
patient should be assessed regularly in conjunction with
an experienced renal dietitian [44]. Optimal nutrition is
necessary to avoid a catabolic state and associated
production of blood urea nitrogen and uremic products.
Rationale
Patients with ARF need constant assessment while on PD,
and adequacy should be judged in terms of clinical status,
ultrafiltration achieved, and biochemical parameters,
particularly urea, creatinine, and bicarbonate levels [40].
Although a link between the dialysis dose and the
outcome of adult patients in ARF has been established
[45], there are no guidelines as to what constitutes
adequate PD in a child with ARF. The aim is to deliver
maximum clearance to compensate for the catabolic
stress.
Complications of acute PD
Leakages can be a difficult problem and are mostly due to
a leakage around the catheter. The incidence can be
reduced by proper surgical technique when using a
Tenkhoff catheter [46] or resuturing around a percutane-
ous catheter. Fibrin glue injected into the catheter tunnel
is a technique under evaluation [47].
Poor drainage due to mechanical blockage or catheter
migration is all too common. Flushing the catheter and
preventing fibrin accumulation by increasing the heparin
dosage and/or urokinase is suggested initially [48]. A
plain abdominal X-ray is rarely justified, as repeated poor
drainage will require catheter relocation. If available, a
laparoscopic technique may be used to correct poor
drainage or replace the malfunctioning catheter [49].
Hernias can be a problem in neonates and infants,
particularly males. They do not usually require interrup-
tion of PD and can be repaired electively by laparoscopic
or direct measures when the child’s clinical condition has
improved or stabilized.
Peritonitis remains a constant threat, especially if there
has been a lot of manipulation of the catheter. The
standard features of cloudy PD fluid require urgent
attention [50].
Continuous extracorporeal techniques
Continuous arteriovenous hemofiltration (CAVH) has
largely been replaced by pumped CVVH and CVVHDF,
particularly in ICUs [51]. Such continuous renal replace-
ment therapies (CRRT) have expanded the possible role
of blood purification in the management of critically ill
patients. However, there is a lack of randomized trials in
patients with sepsis, and a recent analysis failed to show a
benefit for hemofiltration [52]. Studies in adult ICU
patients have shown a lower mortality in patients treated
with CRRT compared with intermittent HD. However, a
recent meta-analysis of studies before 1996 concluded
that the evidence was insufficient to draw strong conclu-
sions regarding the mode of renal replacement therapy for
ARF in the critically ill [53]. A recent randomized trial in
adult ICU patients showed a significant survival advan-
tage when the intensity of ultrafiltration was increased
[54].
Practical guidelines for prescription
Since the concentration of solutes in the filtrate is the
same as in the plasma, biochemistry is controlled by
removing large volumes of filtrate and replacing it with
electrolyte-containing fluid (HF replacement fluid). As
most solutes are distributed within the extracellular and
intracellular fluid compartments (total body water), the
exchange volume of filtration necessary to control
biochemistry relates to total body water. Clinical expe-
rience has shown that a turnover of approximately 50% of
body weight in 24 h is usually adequate for CVVH.
The extracorporeal circuit requires good central ve-
nous access, usually via a dual-lumen catheter, to allow
the high blood flows necessary to prevent clotting in the
hemofilter. Suggested catheter sizes in French gauge (FG)
are:
Patient size (kg) Vascular access
2.5–10 6.5-FG dual-lumen (10 cm)
10–20 8-FG dual-lumen (15 cm)
>20 10.8-FG or larger dual-lumen (20 cm)
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adequate, and access can be obtained via the umbilical
vein [55]. A single-lumen catheter using a “single needle”
for CVVHD in very low birth weight infants has also been
described [56], but this method may be compromised by
high recirculation rates with most available systems.
However, the smaller the access the greater the problems
[57]. It is possible to consider placing two small single-
lumen catheters in different central veins.
A low blood flow rate, high hematocrit, and high
plasma protein concentration will limit the rate at which
filtration can occur and solutes (particularly of higher
molecular weight) are removed. For a given blood flow
rate, pre-dilution results in higher clearance of solutes
than does post-dilution [58], but at the expense of greater
use of replacement fluid (approximately 20%–50% more).
Pre-dilution has the potential for extending filter life.
As with HD, the blood volume in the extracorporeal
circuit should be less than 10% of the patient’s circulatory
volume. Blood flows of 6–9 ml/kg per min or 8% of
circulating blood volume prevents excessive hemocon-
centration in the filter. Automated machines with appro-
priate accuracy for children are recommended for
delivering the CRRT prescription safely [59], and have
replaced pump-assisted hemofiltration using volumetric
pumps [60].
To achieve a 50% exchange of total body water in
24 h, an appropriate filter should be selected with a
surface area of no more than the surface area of the
patient. Suggested maximum filtration rates are:
Patient size (kg) Maximum filtration rate (ml/h)
<8.5 250
8.5–20 500
>20 2,000
Under post-dilution conditions, the filtration rate
should never exceed one-third of the blood flow.
Several filter materials are now available. Synthetic
membranes have replaced cellulose acetate, as they are
more biocompatible, causing less complement reaction
and anticoagulation needs. The synthetic polysuphone
membranes are also thought to aid convective clearance
of solutes through solute drag [61].
A variety of replacement fluids are available such as
lactate, bicarbonate, and buffer-free solutions. Bicarbon-
ate or buffer-free solutions should be used in young
infants and those intolerant of lactate. If a commercially
available bicarbonate solution were freely available, then
this would be the solution of choice. Careful monitoring
of electrolytes, glucose, and phosphate is essential, as the
constituents vary between the solutions.
Anticoagulation
The goals of anticoagulation are to prevent clotting of the
circuit and maintain adequate clearances with minimal
risk to the patient. Heparin is the standard anticoagulant in
Europe, but the choice of dosage will depend upon the
patient’s coagulation status, adequacy of blood flow, and
blood viscosity. In most patients, heparin should be
administered as an initial bolus (maximum 50 units/kg) at
the time of connection to the extracorporeal circuit,
followed by a continuous infusion of 0–30 units/kg per
hour. The activated clotting time (ACT) or whole blood
activated partial thromboplastin time (aPPT) are usually
used to monitor treatment. The optimal ACT during
hemofiltration is 120–180 s. The aPPT should be between
1.2 and 1.5 times the respective baseline value. Some
patients can be treated without heparin in the circuit [6].
In those patients who are severely thrombocytopenic
or where there is suspected heparin-induced thrombocy-
topenia, alternative treatment with prostaglandin infu-
sions or recombinant hirudin [62], a direct thrombin
inhibitor, can be considered [63].
Regional anticoagulation with citrate has been favored
by some centers [64, 65]. Sodium citrate chelates ionized
calcium necessary for the coagulation cascade and
systemic anticoagulation is avoided by infusing calcium
through a separate central line. The disadvantages include
the possibility of various acidbase and electrolyte distur-
bances, including hypernatremia, hypocalcemia, and
metabolic alkalosis.
Adjustment of the prescription
Any formula for the prescription of HF is at best an
approximation or starting point, as the needs will be
determined by many unmeasured variables, such as the
rate of solute production, nutritional intake, and the actual
volumes of the extracellular fluid and intracellular fluid
compartments.
If only fluid removal is required, then relatively low
rates of filtration are needed, often referred to as slow
continuous ultrafiltration (SCUF). There will be negligi-
ble solute removal under these circumstances.
Correction of “uremia” and electrolyte disturbance
requires the turnover of large volumes per kilogram of
fluid, typically of the order of 50% of body weight per
day for post-dilution and 75% for pre-dilution (approx-
imately 20–30 ml/kg per hour).
In catabolic patients, the clearances achieved with
standard CVVH may not be sufficient. Solute removal
may be increased by attempting “high-volume exchange,”
but this may be limited by the practical problems of
pediatric patients with limitations of vascular access and
hemoconcentration in the filter. In these cases, small
solute clearances can be maximized by establishing
diffusive mass transport via a dialysis circuit. This can
be performed with CVVHDF or without an additional
major ultrafiltration component (CVVHD). CVVHDF
latter technique requires an additional pump to achieve
separate control of the dialysate in- and outflow and of the
replacement fluid flow. CVVH substitution fluid bags can
be used as dialysis fluid. Dialysis fluid flow should be 2–3
times the blood flow if maximal efficacy is desired. This
203setting requires frequent manual bag exchanges and
continuous supervision of the system. For practical
purposes, the HD component can be added for several
hours per day to a CVVH regimen.
CVVHD has recently been recommended as the
method of choice for the treatment of inborn errors of
metabolism, since it supplies maximal clearance of
ammonium and other neurotoxic metabolites. When
CVVHD is unavailable, large volume turnover of body
water with CVVH will provide the next best therapy.
Rates of up to 100 ml/kg per hour have been reported
[66]. If possible, the blood pump speed also needs to be
increased.
When high turnover and blood flow rates are in use,
patients should be carefully monitored for hypothermia,
hypokalemia, and circulatory failure. Hypothermia may
need to be treated with an external warming blanket and
hypokalemia will require replacement. Blood flow should
not be increased if the patient develops cardiovascular
instability.
CVVH and extracorporeal membrane oxygenation
In the authors0 experience, the best results are achieved
when pre-diluted fully automated CVVH is used, attached
to the venous (outflow from patient) side of the
extracorporeal membrane oxygenation (ECMO) circuit.
This appears to reduce problems of shunting blood around
the oxygenator and overcomes the problems of the
increased hematocrit that may be associated with ECMO.
It also reduces the complications of excessive fluid and
solute clearances, with a free flow when systemic
hemofilters are used in line with the ECMO circuit.
When using CVVH in the suggested configuration, the
“pigtails” provide access with very little resistance,
causing the arterial and venous pressure alarms to activate
and shut down the circuit. Therefore, three-way taps are
used to create more resistance to flow into and out of the
CVVH circuit. When treating neonatal patients, the
ECMO circuit increases the extracorporeal blood volume
very significantly. Therefore, the blood pump speed
should be calculated taking into account the patient’s
blood volume and the priming volume of the ECMO
circuit.
Complications of continuous extracorporeal techniques
Complications of continuous extracorporeal techniques
are described in reference [67].
Hypotension
Hemofiltration is most commonly used in sick septic
children, many of whom will be on pressor therapy.
Indeed, the need for pressor agents gives a poorer
prognosis [6]. Care should have been taken to minimize
the amount of blood in the extracorporeal circuit and
blood priming of the HF circuit may be necessary at the
outset. Fluid removal is obviously adjusted according to
the patient’s clinical state during the treatment.
Clotting of the filter and lines
This is one of the commonest complications and again is
related to the patient’s changing clinical status and
problems with anticoagulation. This complication oc-
curred in 24% of 89 patients treated with CVVH in a 2-
year local audit (B. Harvey, unpublished observations).
Other potential complications of bleeding, anticoagu-
lation toxicity, and infections appear to be minimal. Air
embolism is a rare but preventable complication of
extracorporeal circuits, and is greatly reduced with the
proper use of automated machinery.
Intermittent HD
The advantages and limitations
of intermittent HD are described in reference [68].
Advantages
The main advantage of HD is the relatively rapid removal
of uremic toxins and ultrafiltration of fluid. This makes
the technique well suited for acute situations.
Limitations
HD is not a continuous therapy and it requires good
vascular access as with HF. A purified water supply is
also required, as well as anticoagulation, which should
always be minimized. The technique might not be
applicable for hemodynamically unstable patients. Often
the major limiting factor is the availability of expert
nursing staff [69], especially in the ICU [70].
Practical guidelines for prescription
HD is only possible with good vascular access provided
either by a double-lumen HD catheter or a single-lumen
catheter of sufficient diameter to achieve flows for single-
needle dialysis. Catheter lengths vary from 5 cm for
neonates to 20 cm for large adolescents.
Bloodline choice depends on the priming (extracorpo-
real) volume, which traditionally has not exceeded 10%
of the blood volume (approximately 80 ml/kg).
Dialyzer choice depends on the priming volume and
maximum flow rate, with a surface area that should not
exceed the child’s surface area and with a urea clearance
between 3 and 5 ml/kg per min. There is no evidence for
dialyzer choice in pediatric practice, but meta-analysis in
204adult patients with ARF suggested synthetic membranes
conferred a significant survival advantage over cellulose-
based membranes, but with no similar benefit for
recovery of renal function [71].
Bloodline priming is usually performed with isotonic
saline. Small babies, anemic patients, and those in an
unstable cardiocirculatory condition, require priming with
albumin or blood.
HD catheter care
After the session the catheter should be flushed with
isotonic saline and filled with undiluted heparin
(1,000 IU/ml), with volumes according to manufacturer’s
recommendations (usually marked on the catheter itself).
HD prescription
The first session should not exceed 2–3 h, but the standard
time is usually 4 h. Longer sessions are advisable to avoid
too-rapid ultrafiltration and disequilibrium syndrome.
All children should be dialyzed using volume-con-
trolled machines and with bicarbonate dialysate.
The blood pump rate is usually 6–8 ml/kg per min, but
depends upon the catheter and patient size [69].
The ultrafiltration target should not exceed 0.2 ml/kg
per min for acute patients who should be carefully
monitored for hypovolemia and hypotension. Sodium
profiling is rarely used in pediatric HD practice. Antico-
agulation is usually with heparin (50–100 IU/kg per
session including initial bolus). Reinfusion is usually
performed with isotonic saline.
Complications occurring during acute HD
For hypotension, the ultrafiltration should be switched off
and isotonic saline infused into the venous line until the
blood pressure normalizes; additional 20% albumin 5 ml/
kg might be helpful.
Hypertension is treated according to standard hyper-
tension protocols available elsewhere [72].
Disequilibrium syndrome is now a rare event with
adequate control of ultrafiltration and stepwise reduction
of uremic toxins.
Hypoglycemia should not occur with the use of
glucose-containing dialysis fluid.
In cases of anemia transfusions are avoided unless
patient symptomatic. Erythropoietin may be given intra-
venously at the end of dialysis (50–200 IU/kg) to maintain
hemoglobin levels.
Medications
The clearance of drugs on HD or during CRRT needs to
be considered. Reference should be made to standard
texts [73, 74].
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